ClinicalTrials.gg
Not yet recruitingNCT07543497Updated Apr 22, 2026

Performance and Impact of the Sepsis ImmunoScore

An observational study in Sepsis, sponsored by Prenosis, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Prenosis, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.

02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • sepsis
03

In context

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Prenosis, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults 18 years or older presenting to the hospital or ED, suspected of clinically significant events, including sepsis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (age 18 years or older) patients presenting to hospitals and emergency departments of medical institutions across the United States.
  • Adult (age 18 years or older) patients suspected of sepsis.

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adult patients at risk of clinically significant events
  • Adult patients suspected of sepsis

    Diagnostic Test: Sepsis ImmunoScore

Interventions

  • Diagnostic testSepsis ImmunoScore

    The Sepsis ImmunoScore is a risk stratification tool that uses Artificial Intelligence/Machine Learning to aid in the identification of patients likely to have or progress to sepsis within 24 hours of assessment.

06

What researchers measure

Primary outcomes

  1. Sepsis diagnosis

    meeting sepsis-3 criteria within 24 hours of Sepsis ImmunoScore order

    Time frame: 24 hours

  2. SEP-1 bundle compliance

    proportion of patients meeting SEP-1 bundle criteria for whom all bundle components are delivered within the required time frame

    Time frame: through study completion, an average of 1 year

  3. Number of clinically significant events such as infection, sepsis, critical care interventions, escalation of care, mortality

    (e.g., vasopressor support, renal replacement therapy, non-invasive or invasive respiratory ventilation)

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Time to antibiotic administration

    Time frame: through study completion, an average of 1 year

  2. Coding compliance including appropriate clinical documentation to justify a diagnosis of sepsis

    Time frame: through study completion, an average of 1 year

  3. Hospital length of stay

    Time frame: through study completion, an average of 1 year

  4. ICU length of stay

    Time frame: through study completion, an average of 1 year

  5. Total charges

    Time frame: through study completion, an average of 1 year

  6. In-hospital mortality rate

    28-day in-hospital mortality rate defined as the proportion of patients with a discharge disposition of "died" prior to 28 days

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 52 industry-sponsored observational studies under Sepsis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 44. This study's planned 20 months is above that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Apr 22, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07543497
Lead sponsor
Prenosis, Inc.
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Grace Staples
Contact
grace.staples@prenosis.com
(312) 235-3580

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion